

Antonio Maria Risitano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4666984/publications.pdf>

Version: 2024-02-01

161
papers

9,592
citations

44066

48
h-index

39667

94
g-index

187
all docs

187
docs citations

187
times ranked

7881
citing authors

#	ARTICLE	IF	CITATIONS
1	How we(â€™) treat paroxysmal nocturnal haemoglobinuria: diving into the future. British Journal of Haematology, 2022, 196, 288-303.	2.5	27
2	Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood, 2022, 139, 3571-3582.	1.4	33
3	Upfront unrelated donor hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: A retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation. American Journal of Hematology, 2022, 97, .	4.1	7
4	Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress. Seminars in Hematology, 2022, 59, 38-46.	3.4	4
5	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 399-406.	2.4	9
6	Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls. Seminars in Immunology, 2022, 59, 101618.	5.6	9
7	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Clinical Cancer Research, 2021, 27, 843-851.	7.0	25
8	Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis. Digestive Diseases and Sciences, 2021, 66, 408-411.	2.3	0
9	Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2021, 384, 1028-1037.	27.0	187
10	Stem Cell Transplantation for Diamondâ€™Blackfan Anemia. A Retrospective Study on Behalf of the Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT). Transplantation and Cellular Therapy, 2021, 27, 274.e1-274.e5.	1.2	14
11	Haploâ€™identical or mismatched unrelated donor hematopoietic cell transplantation for <scp>Fanconi</scp> anemia: Results from the <scp>Severe Aplastic Anemia Working Party</scp> of the <scp>EBMT</scp>. American Journal of Hematology, 2021, 96, 571-579.	4.1	14
12	Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. International Journal of Hematology, 2021, 114, 228-234.	1.6	16
13	Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematology, the, 2021, 8, e344-e354.	4.6	56
14	Special issues related to theâ€™diagnosis and management of acquired aplastic anemia in countries with restricted resources, aâ€™report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT). Bone Marrow Transplantation, 2021, 56, 2518-2532.	2.4	7
15	Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplantation, 2021, 56, 2600-2602.	2.4	27
16	Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood, 2021, 138, 1928-1938.	1.4	45
17	Efficacy matters: broadening complement inhibition in COVID-19. Lancet Rheumatology, The, 2021, 3, e95.	3.9	6
18	Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica, 2021, 106, 3188-3197.	3.5	52

#	ARTICLE	IF	CITATIONS
19	Infectious Agents and Bone Marrow Failure: A Causal or a Casual Connection?. <i>Frontiers in Medicine</i> , 2021, 8, 757730.	2.6	6
20	Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy. <i>Blood</i> , 2021, 138, 4313-4313.	1.4	0
21	Categorized Hematologic Response to Pegcetacoplan and Correlations with Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from Phase 1b, Phase 2a, and Phase 3 Trials. <i>Blood</i> , 2021, 138, 1104-1104.	1.4	5
22	HLA in AA: innocent bystander or culprit?. <i>Blood</i> , 2021, 138, 2744-2745.	1.4	0
23	3113 “ FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECUZUMAB TREATMENT. <i>Experimental Hematology</i> , 2021, 100, S97.	0.4	3
24	Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 1050-1058.	2.4	42
25	Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. <i>Clinical Immunology</i> , 2020, 220, 108598.	3.2	191
26	Hepatitis-associated aplastic anemia. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, , .	0.9	13
27	Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH). <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 249.	2.7	8
28	Impact of donor age and kinship on clinical outcomes after T-cell“replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , 2020, 4, 3900-3912.	5.2	30
29	Ruxolitinib for steroid-resistant acute GVHD. <i>Blood</i> , 2020, 135, 1721-1722.	1.4	12
30	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. <i>Clinical Immunology</i> , 2020, 215, 108450.	3.2	252
31	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1223-1231.	3.5	34
32	Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1906-1917.	2.4	33
33	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <sc>EBMT</sc> group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	4.1	30
34	Complement as a target in COVID-19?. <i>Nature Reviews Immunology</i> , 2020, 20, 343-344.	22.7	426
35	Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , 2020, 106, 230-237.	3.5	77
36	Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. <i>British Journal of Haematology</i> , 2020, 191, 476-485.	2.5	38

#	ARTICLE	IF	CITATIONS
37	Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 35-37.	1.4	2
38	Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT. Blood, 2020, 136, 45-47.	1.4	0
39	Transfusion Requirements in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria with or without a History of Bone Marrow Disorder Receiving Ravulizumab and Eculizumab: Results from a Phase 3 Non-Inferiority Study Extension. Blood, 2020, 136, 31-33.	1.4	0
40	Categorized Hematologic Response to Pegcetacoplan Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis of Data from a Phase 3 Randomized Trial (PEGASUS). Blood, 2020, 136, 44-45.	1.4	1
41	Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors. Blood, 2020, 136, 43-44.	1.4	3
42	Upfront Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Idiopathic Aplastic Anemia: A Study on Behalf of the Saawp of EBMT. Blood, 2020, 136, 11-13.	1.4	0
43	Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors. Blood, 2020, 136, 34-34.	1.4	2
44	Gvhd and Relapse Free Survival (GRFS) after Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT. Blood, 2020, 136, 3-4.	1.4	1
45	Allogeneic stem cell transplantation for acquired pure red cell aplasia. American Journal of Hematology, 2019, 94, E294-E296.	4.1	9
46	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). Biology of Blood and Marrow Transplantation, 2019, 25, 2388-2397.	2.0	33
47	Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Frontiers in Immunology, 2019, 10, 1157.	4.8	133
48	“Stealth” corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology, 2019, 20, 1409-1413.	14.5	7
49	Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplantation, 2019, 54, 1346-1353.	2.4	43
50	The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2019, 25, e277-e284.	2.0	17
51	Use of eltrombopag in aplastic anemia in Europe. Annals of Hematology, 2019, 98, 1341-1350.	1.8	30
52	Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7926-7931.	7.1	116
53	T-PLL: harmonizing criteria for research. Blood, 2019, 134, 1113-1114.	1.4	1
54	Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica, 2019, 104, 919-928.	3.5	34

#	ARTICLE	IF	CITATIONS
55	Impact of Tâ€cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. American Journal of Hematology, 2019, 94, 80-86.	4.1	16
56	Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitorâ€experienced adult patients with PNH: the 302 study. Blood, 2019, 133, 540-549.	1.4	239
57	Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. British Journal of Haematology, 2019, 184, 294-298.	2.5	7
58	Severe Aplastic Anemia and PNH. , 2019, , 579-585.		8
59	A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy. Blood, 2019, 134, 3514-3514.	1.4	12
60	Hematological Response to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify Unmet Clinical Needs and Future Clinical Goals. Blood, 2019, 134, 3517-3517.	1.4	8
61	Stem Cell Transplantation for Diamond-Blackfan Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT). Blood, 2019, 134, 44-44.	1.4	10
62	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology, 2018, 55, 167-175.	3.4	32
63	Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 2018, 93, 564-577.	4.1	45
64	(Auto-)immune signature in aplastic anemia. Haematologica, 2018, 103, 747-749.	3.5	6
65	Acute immune toxicity during antiâ€thymocyte globulin: That's CARPA!. American Journal of Hematology, 2018, 93, E22-E24.	4.1	3
66	Transplant results in adults with Fanconi anaemia. British Journal of Haematology, 2018, 180, 100-109.	2.5	25
67	Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 119-126.	2.0	37
68	Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions. British Journal of Haematology, 2018, 183, 133-136.	2.5	11
69	Therapeutic complement modulation for hematological diseases: Where we stand and where we are going. Seminars in Hematology, 2018, 55, 113-117.	3.4	1
70	Advances in understanding the pathogenesis of acquired aplastic anaemia. British Journal of Haematology, 2018, 182, 758-776.	2.5	91
71	Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. British Journal of Haematology, 2018, 183, 110-118.	2.5	53
72	Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies. Blood, 2018, 132, 626-626.	1.4	7

#	ARTICLE	IF	CITATIONS
73	A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2018, 132, 2330-2330.	1.4	4
74	Outcome of Transformed Fanconi Anaemia Patients after Hematopoietic Stem Cell Transplantation: Analysis on Behalf of European Group for Blood and Marrow Transplantation. Blood, 2018, 132, 646-646.	1.4	0
75	Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab. Blood, 2018, 132, 625-625.	1.4	0
76	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. Expert Opinion on Biological Therapy, 2017, 17, 821-836.	3.1	4
77	Immune insights into AA. Blood, 2017, 129, 2824-2826.	1.4	3
78	Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes. Journal of Hematology and Oncology, 2017, 10, 126.	17.0	28
79	Clinical Effects of Eculizumab in PNH: Extravascular Hemolysis After Eculizumab Treatment. , 2017, , 283-295.		1
80	Future Strategies of Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria. , 2017, , 319-346.		0
81	Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition. American Journal of Hematology, 2016, 91, 359-360.	4.1	4
82	Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 2016, 91, E16-7.	4.1	13
83	Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned. Haematologica, 2016, 101, 319-327.	3.5	52
84	Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical Immunology, 2016, 171, 32-35.	3.2	23
85	Small-molecule factor D inhibitors targeting the alternative complement pathway. Nature Chemical Biology, 2016, 12, 1105-1110.	8.0	68
86	Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Seminars in Immunology, 2016, 28, 223-240.	5.6	36
87	Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions. Blood, 2016, 128, 1505-1505.	1.4	1
88	CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab). Blood, 2016, 128, 401-401.	1.4	6
89	Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study. Blood, 2016, 128, 2285-2285.	1.4	15
90	Complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going. Expert Opinion on Orphan Drugs, 2015, 3, 691-704.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Dissecting complement blockade for clinic use. Blood, 2015, 125, 742-744.	1.4	12
92	Similar outcome of upfront unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the <scp>UK</scp> Paediatric <scp>BMT</scp> Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of <scp>EBMT</scp>. British Journal of Haematology, 2015, 171, 585-594.	2.5	146
93	Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. British Journal of Haematology, 2015, 169, 565-573.	2.5	104
94	Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood, 2015, 126, 891-894.	1.4	89
95	Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America, 2015, 29, 561-582.	2.2	30
96	Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation, 2015, 45, 423-440.	3.4	178
97	Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2015, 373, 1032-1039.	27.0	201
98	Applying complement therapeutics to rare diseases. Clinical Immunology, 2015, 161, 225-240.	3.2	60
99	Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). Annals of Hematology, 2015, 94, 531-534.	1.8	12
100	Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients. Blood, 2015, 126, 2137-2137.	1.4	20
101	Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2014, 99, 1574-1581.	3.5	73
102	Hematopoietic stem cell transplantation for aplastic anemia and paroxysmal nocturnal hemoglobinuria: current evidence and recommendations. Expert Review of Hematology, 2014, 7, 775-789.	2.2	12
103	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology, 2014, 7, 583-598.	2.2	43
104	Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica, 2014, 99, 262-266.	3.5	77
105	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation, 2014, 20, 872-880.	2.0	141
106	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood, 2014, 123, 2094-2101.	1.4	172
107	Clonal non-malignant hematological disorders: unraveling molecular pathogenic mechanisms to develop novel targeted therapeutics. Translational Medicine @ UniSa, 2014, 8, 1-3.	0.5	1
108	Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going. Translational Medicine @ UniSa, 2014, 8, 43-52.	0.5	14

#	ARTICLE	IF	CITATIONS
109	Paroxysmal Nocturnal Hemoglobinuria and the Complement System: Recent Insights and Novel Anticomplement Strategies. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 155-172.	1.6	67
110	Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2013, 162, 62-73.	2.5	320
111	Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties. <i>Journal of Immunology</i> , 2013, 190, 5712-5721.	0.8	137
112	Outcome Of Aplastic Anemia In Adolescence. A Survey Of The Severe Aplastic Anemia Working Party (SAAWP) Of The European Blood and Bone Marrow Transplant Group (EBMT). <i>Blood</i> , 2013, 122, 2481-2481.	1.4	0
113	Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. <i>Haematologica</i> , 2012, 97, 1142-1148.	3.5	167
114	Immunosuppressive therapies in the management of acquired immune-mediated marrow failures. <i>Current Opinion in Hematology</i> , 2012, 19, 3-13.	2.5	16
115	The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization. <i>Blood</i> , 2012, 119, 6307-6316.	1.4	115
116	Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. <i>Blood</i> , 2012, 119, 5391-5396.	1.4	156
117	Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. <i>Immunobiology</i> , 2012, 217, 1080-1087.	1.9	71
118	From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging. <i>British Journal of Haematology</i> , 2012, 158, 415-418.	2.5	15
119	Outcome of Aplastic Anemia in Children. A Survey On Behalf of the SAA and PDWP of the EBMT. <i>Blood</i> , 2012, 120, 643-643.	1.4	0
120	Optimization of Therapy for Severe Aplastic Anemia Based on Clinical, Biologic, and Treatment Response Parameters: Conclusions of an International Working Group on Severe Aplastic Anemia Convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 291-299.	2.0	31
121	Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. <i>Blood</i> , 2011, 118, 4705-4713.	1.4	117
122	Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going. <i>British Journal of Haematology</i> , 2011, 152, 127-140.	2.5	23
123	Aplastic anemia: immunosuppressive therapy in 2010. <i>Mental Illness</i> , 2011, 3, 7.	0.8	3
124	Prospective Phase II Pilot Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline) with Ciclosporin for Patients with Acquired Aplastic Anemia and Matched Pair Analysis with Patients Treated with Horse ATG (Lymphoglobuline) and Ciclosporin: A Study From the EBMT Severe Aplastic Anemia Working Party (RATGAA07). <i>Blood</i> , 2011, 118, 2408-2408.	1.4	1
125	Paroxysmal nocturnal hemoglobinuria and eculizumab. <i>Haematologica</i> , 2010, 95, 523-526.	3.5	62
126	Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. <i>British Journal of Haematology</i> , 2010, 148, 791-796.	2.5	63

#	ARTICLE	IF	CITATIONS
127	Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Haematologica, 2010, 95, 983-988.	3.5	64
128	Paroxysmal Nocturnal Hemoglobinuria “ Hemolysis before and after Eculizumab. New England Journal of Medicine, 2010, 363, 2270-2272.	27.0	59
129	Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2010, 116, 4237-4237.	1.4	4
130	Matched Sibling Transplants for Aplastic Anemia: Survival Advantage for Marrow Vs Peripheral Blood Transplants, In All Age groups. Blood, 2010, 116, 523-523.	1.4	2
131	C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes. Blood, 2010, 116, 637-637.	1.4	1
132	TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis. Blood, 2010, 116, 638-638.	1.4	0
133	Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. Annals of Hematology, 2009, 88, 1261-1262.	1.8	4
134	Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood, 2009, 113, 4094-4100.	1.4	273
135	TT30, a Novel Regulator of the Complement Alternative Pathway (CAP), Inhibits Hemolysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes and Prevents Upstream C3 Binding On Their Surface in An in Vitro Model.. Blood, 2009, 114, 158-158.	1.4	8
136	Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency.. Blood, 2009, 114, 3012-3012.	1.4	3
137	Clinical Impact of Unregulated Terminal Complement Activity in Never-Transfused Patients with Paroxysmal Nocturnal Hemoglobinuria.. Blood, 2009, 114, 4029-4029.	1.4	3
138	Terminal Complement Inhibitor Eculizumab Improves Complement-Mediated Platelet Consumption and Thrombocytopenia in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).. Blood, 2009, 114, 4030-4030.	1.4	9
139	From Renal Siderosis Due to Perpetual Hemosiderinuria to Possible Liver Overload Due to Extravascular Hemolysis: Changes in Iron Metabolism in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients On Eculizumab.. Blood, 2009, 114, 4031-4031.	1.4	2
140	Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood, 2008, 111, 1840-1847.	1.4	534
141	Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood, 2008, 112, 449-451.	1.4	47
142	Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents. Biologics: Targets and Therapy, 2008, 2, 205.	3.2	54
143	Function and Malfunction of Hematopoietic Stem Cells in Primary Bone Marrow Failure Syndromes. Current Stem Cell Research and Therapy, 2007, 2, 39-52.	1.3	37
144	Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood, 2007, 110, 4123-4128.	1.4	481

#	ARTICLE	IF	CITATIONS
145	Subcutaneous Alemtuzumab Is Safe and Effective for Treatment of Global or Single-Lineage Immune-Mediated Marrow Failure: A Pilot Study.. Blood, 2007, 110, 1692-1692.	1.4	1
146	The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine, 2006, 355, 1233-1243.	27.0	1,060
147	Paroxysmal Nocturnal Hemoglobinuria. , 2006, , 838-847.		46
148	Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization.. Blood, 2006, 108, 972-972.	1.4	5
149	Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cellâ€“receptor restriction in large granular lymphocyte leukemia. Blood, 2005, 106, 2769-2780.	1.4	107
150	New Challenges to Developing Animal Models for Human Immune-Mediated Marrow Failure. Clinical Medicine and Research, 2005, 3, 63-64.	0.8	3
151	Aplastic Anemia: Management of Adult Patients. Hematology American Society of Hematology Education Program, 2005, 2005, 110-117.	2.5	19
152	Molecular Analysis of TCR Clonotypes in LGL: A Clonal Model for Polyclonal Responses. Journal of Immunology, 2004, 172, 1960-1969.	0.8	66
153	Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 2004, 125, 804-813.	2.5	115
154	In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR Î²-CDR3 sequencing. Lancet, The, 2004, 364, 355-364.	13.7	223
155	CD34+ cells from paroxysmal nocturnal hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion protein (PrP c). Experimental Hematology, 2003, 31, 65-72.	0.4	10
156	Application of the Molecular Analysis of the T-Cell Receptor Repertoire in the Study of Immune-Mediated Hematologic Diseases. Hematology, 2003, 8, 173-181.	1.5	57
157	Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood, 2002, 99, 3668-3675.	1.4	59
158	Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by VÎ²2 CDR3 spectratyping and flow cytometry. Blood, 2002, 100, 178-183.	1.4	119
159	Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood, 2002, 99, 3129-3135.	1.4	228
160	A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)â€“Fc fusion protein in patients with myelodysplastic syndrome. British Journal of Haematology, 2002, 117, 119-126.	2.5	63
161	Complement as a target in COVID-19?. , 0, .		1